Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

Healthcare Biotechnology
ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

ProMIS Neurosciences Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(2)
•••
Post by Trek1701on Jul 15, 2022 1:34am
297 Views
Post# 34826099

4cent dingleberry

4cent dingleberry

It's a good thing PMN is working on a treatment for schizophrenia, but it may not arrive in time. Maybe we will find out in 3-5 years. Until then BUY AND HOLD?

April 07, 2021 - 12:18 PM
136 Reads 
Post# 32949667

RE:RE:RE:Slow and steady pace in the right direction for share price

I don't believe this to be the case regarding the New Investors from Fenway Group and The Kraft Group. They are long term Investors and their Debtentures will Expire in 2026. By that time the goal is to get listed on the Nasdaq, meaning the potential Share Price to $1.00-$3.00 by End of 2023. Buy and HOLD!
April 07, 2021 - 12:20 PM
179 Reads 
Post# 32949686

RE:RE:RE:Slow and steady pace in the right direction for share price

It will definetely be interesting to see what this Year brings, don't forget they are also looking for a New CEO for 2022. There is no way the New Investors will bail after the June 2021 hearing on Aducanumab. This is long term buy and hold. 3-5 Years. 
April 15, 2021 - 11:56 AM
103 Reads 
Post# 33000822

RE:RE:RE:PMN wishes from three weeks ago.. 

PMN.to is a long term buy and hold. The new Investors and their debentures expire in 2026. Their goal is to to be listed on the Nasdaq meaning the Stock Price will only rise. Once you notice people are buying and the price is not going up, you can always sell and buy in at a lower point and own more shares. PMN.to is not going anywhere and will contine to strive!
April 29, 2021 - 01:04 PM
148 Reads 
Post# 33094170

RE:how many non-exclusive licenses might there be???

Any amount under 0.19 is a great buy and hold. Lots of news coming up including the FDA's ruling on Aducanumab and PMN is also searching for a new CEO. Also, the Debentures expire in 2026, so if you are looking for somewhere to hold your savings, PMN is an excellent 4-5 year choice. 
May 06, 2021 - 06:35 PM
100 Reads 
Post# 33148882

RE:RE:RE:RE:RE:RE:Dr. Chin is all over the news

I've owned PMN since last November and bought in at .10 and have already doubled my money. I will not sell any shares of PMN and will continue to buy more below .20. 
I don't believe anyone on this Forums has inside information, so for anyone asking please do your own DD. Personally, PMN is an excellent Company to be invested in for the next 3-5 Years. Stock Price will not stay around 0.15-0.20. There will be a breaking point and only after that will we see high returns. I have stated in the past that PMN.to is a Long Term Buy and Hold. Cheers!
May 17, 2021 - 12:42 AM
141 Reads 
Post# 33212413

RE:RE:PMN.to is undervalued; Example in BIIB. LLY and I-MAB

Been holding for 1 year now and will never sell unless I have to. Excellent Company and New CEO coming soon. This is the one Company that Aducanumab will not affect as much as Biib. Long term Buy and Hold. Invest and forget it. Come back in 10 Years. 
May 19, 2021 - 12:14 AM
86 Reads 
Post# 33228045

RE:RE:RE:RE:RE:For newbies wanting to learn about PMN310

The only reason this stock is not trading below 0.10 is because of the FSG Group and the other new Investors. Excellent Company to hold for 3-5 Years. 
May 20, 2021 - 10:52 AM
111 Reads 
Post# 33237357

RE:RE:Why April 1st?

The only reason PMN.to is staying above 0.17 is because of the new Investors and Board of Directors. Even if Aducanumab is rejected, I don't see the price dropping 60%. If it does, I'm buying all the Stocks available!
May 21, 2021 - 09:44 PM
100 Reads 
Post# 33253125

RE:Twitter handle active again 

Awesome find! Been with PMN.to for almost 2 Years and will continue to Buy and Hold. We need to find the solution for Alzheimer's Disease, Parkinsons and many other Brain Illnesses. This is our future!
June 16, 2021 - 10:57 AM
136 Reads 
Post# 33395087

RE:RE:RE:RE:RE:RE:RE:RE:Game Plan

I'm not really too sure what you want Gene and Elliot to do? With the Boston Group having already Invested "Millions" of Dollars and the Approval of Aducanumab I don't believe Gene or Elliot are steering the Ship anymore. Keep in mind I have only been Invested for 1 year now and don't know too much about their previous endeavours. 
I'm curious as to who they have in mind for a new CEO come Years End. Any speculations? This too will definitely Increase the SP when it is announced. As RC has stated in the past, PMN can be a volatile stock and you have to learn when to Buy the dip and Sell soon after a PR is released. This way you can accumulate more Shares and when PMN hits 1-2 Dollar mark I am buying all you guys Beer and Chips! I have a special bottle of Crown Royal for my friend M101 ;)
June 22, 2021 - 11:24 PM
141 Reads 
Post# 33432438

RE:RE:Zachs News Article mentioning Biogen and PMN ARFXF

Indeed excellent News for PMN.to ARFXF! Imagine buying now and Biogen actually using PMN310. The SP will rise well above $1.00-$3.00. This is a Buy at the current SP and is a Long Term Investment (3-5 Years Exit). 
June 23, 2021 - 12:21 AM
95 Reads 
Post# 33432595

RE:Timing

2021 YTD 115%

If someone lost Money this year investing with PMN.to ARFXF, you are in the wrong Business.
November 22, 2021 - 01:03 PM
245 Reads 
Post# 34153534

I'm in the Red

Well it's not looking to good on the current Shareholders, price is falling as we speak. 
I believe there will be some PR before the Consolidation occurs which we may see a few points upwards, some can Sell at this point. As for others, post-consolidation may increase the SP but without any Plan going forward we may even see further decrease in SP. 
Curious as to what others are doing, it seems like alot of people of Selling at losses. I don't mind being not able to sell as I don't need the Money right now. 

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities